STOCKHOLM, den 6 mars 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att 100 Emollivet-aktier, motsvarande ca 0,7 MSEK, har avyttrats till Cerbios-Pharma SA. Lipidor genomför, som tidigare meddelats, en stegvis avyttring av sitt innehav i djurbolaget Emollivet AB. Totalt har idag 100 aktier i Emollivet sålts till Cerbios-Pharma SA […]
STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding to approximately SEK 0.7 million, have been divested to Cerbios-Pharma SA. As previously announced, Lipidor is carrying out a step-by-step divestment of its holding in the animal company Emollivet AB. A total of […]
STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception in 2019, Emollivet has held […]
STOCKHOLM, den 24 januari 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att ett av bolagets patent, som tidigare ut-licensierats till Emollivet AB, nu har avyttrats till samma part. Försäljningen syftar till att kortsiktigt stärka Lipidors kassa. Emollivet har sedan sin start år 2019 haft en licens på Lipidors´s IP […]
STOCKHOLM, Sweden, 20th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company, through its partner Cliantha Research, has submitted an application to the Indian Medical Products Agency to start a Phase III study with the drug candidate AKP02G2. The main purpose of the study is to compare […]
STOCKHOLM, den 20 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget genom sin samarbetspartner Cliantha Research har lämnat in en ansökan till indiska läkemedelsmyndigheten om att få starta en Fas III-studie med läkemedelskandidaten AKP02G2. Studiens främsta syfte är att jämföra den terapeutiska effekten hos AKP02G2 med Enstilar […]
STOCKHOLM, den 30 november 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ). Lipidor har ingått avtal med Carnegie Investment Bank AB (publ) avseende tjänsten som Certified Adviser. Carnegie Investment Bank AB (publ) tillträder som […]
STOCKHOLM, Sweden, 30th November 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Lipidor has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB […]
STOCKHOLM, Sweden, 27th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2. In line with Lipidor's strategy, the […]
STOCKHOLM den 27 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget har lämnat in en ny patentansökan till den europeiska patentmyndigheten (European Patent Office, EPO). Patentet är sprunget ur den utveckling som skett under omformuleringsarbetet med AKP02, numera AKP02G2. I linje med Lipidors strategi ser bolaget kontinuerligt […]